Welcome to our dedicated page for McKesson SEC filings (Ticker: MCK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The McKesson Corporation (NYSE: MCK) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about McKesson’s healthcare services and pharmaceutical distribution activities, capital structure, governance, and financial reporting.
McKesson’s common stock and several series of notes, including 1.500% Notes due 2025, 1.625% Notes due 2026, and 3.125% Notes due 2029, are listed on the New York Stock Exchange, as shown in multiple Form 8-K filings. Filings such as Form 8-K report material events, including preliminary quarterly results, updated fiscal guidance, changes to reportable segments, and investor events like Investor Day. A Form 25 filing for 1.500% Notes due 2025 illustrates how specific debt securities can be removed from listing and registration on an exchange.
Investors can also review proxy materials, such as the definitive proxy statement (DEF 14A), which describes McKesson’s purpose, values, Board oversight, compensation matters, and shareholder voting results. These documents provide context on corporate governance, culture, and strategic priorities, including the company’s focus on North American pharmaceutical distribution, oncology and biopharma services platforms, and portfolio modernization.
On Stock Titan, SEC filings for MCK are updated from EDGAR and presented with AI-powered summaries designed to clarify key points in lengthy documents. Users can quickly identify the nature of each filing, from current reports on Form 8-K to proxy statements and other disclosures, and use AI-generated insights to understand segment changes, capital allocation decisions, and governance topics without reading every line of the underlying text.
This page is a useful starting point for reviewing McKesson’s regulatory history, tracking material events, and examining how the company communicates financial and strategic information through its SEC submissions.
McKesson Corporation (MCK) has filed a DEFA14A with the U.S. Securities and Exchange Commission, indicating the submission of definitive additional proxy soliciting materials. The filing is made by the registrant itself, and the company has marked the box showing that no filing fee is required. No preliminary proxy, confidential treatment, or soliciting material under Rule 14a-12 boxes were selected. Beyond these administrative details, the document contains no financial data, transactional information, or new proposals.
McKesson Corporation (MCK) has filed its Definitive Proxy Statement (DEF 14A) ahead of the June 20, 2025 Annual Meeting. The document emphasises the Board’s oversight of culture, strategy and long-term value creation under the company’s purpose, “Advancing Health Outcomes for All®.” Independent Chair Donald R. Knauss thanks shareholders for their ongoing support and outlines how the Board has monitored execution against four stated priorities: 1) focus on people and culture, 2) strengthen North-American pharmaceutical distribution, 3) modernise and accelerate the portfolio, and 4) enhance oncology and biopharma services platforms.
Operational progress in FY 2025:
- Share-price performance: disciplined execution across the business contributed to a 25 % increase in McKesson’s stock price during FY 2025.
- Portfolio optimisation: in December, McKesson divested its Canada-based Rexall and Well.ca businesses, freeing capital for oncology and biopharma services investments.
- Customer momentum: the company onboarded several new customers and expanded a key pharmaceutical distribution relationship, reinforcing its sourcing and distribution capabilities.
- Digital enablement: a company-wide training programme is promoting a digital-first mindset, including the use of artificial intelligence, to drive efficiency and value creation.
- Regulatory posture: the Board states it continues to oversee McKesson’s commitment to “regulatory excellence and compliance with applicable laws.”
Human-capital highlights: Management stresses its I²CARE values (Integrity, Inclusion, Customer-First, Accountability, Respect, Excellence) and ILEAD leadership framework as cultural cornerstones designed to unite its global workforce and sustain performance.
The proxy statement is marked “Definitive,” no filing fee is required, and no preliminary or additional solicitation materials accompany the submission. Financial tables referenced in the XBRL block appear to relate mainly to executive compensation and equity-award valuation; specific dollar amounts, cash-flow figures or earnings data are not included in the excerpt.
For investors, the filing provides qualitative confirmation that McKesson is aligning capital deployment and talent development with its stated strategy, while the 25 % share-price appreciation and Canada divestiture represent tangible outcomes of that strategy.